Disposition of 84000 shares by Robinson Chandler of Monopar Therapeutics at 0.001 subject to Rule 16b-3

MNPR Stock  USD 30.68  3.98  14.91%   
Slightly above 73 percent of all Monopar Therapeutics' retail investors are curious in acquiring. The analysis of the overall investor sentiment regarding Monopar Therapeutics suggests that quite a few traders are confidant. Monopar Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Monopar Therapeutics. Many technical investors use Monopar Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Monopar Therapeutics Director, Officer: Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 84000 stock options at 0.001 of Monopar Therapeutics by Robinson Chandler on 28th of May 2024. This event was filed by Monopar Therapeutics with SEC on 2024-05-28. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Monopar Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Monopar Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Monopar Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Monopar Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Monopar Therapeutics Fundamental Analysis

We analyze Monopar Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monopar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monopar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Income

Net Income Comparative Analysis

Monopar Therapeutics is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Monopar Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Monopar Therapeutics stock to make a market-neutral strategy. Peer analysis of Monopar Therapeutics could also be used in its relative valuation, which is a method of valuing Monopar Therapeutics by comparing valuation metrics with similar companies.

Peers

Monopar Therapeutics Related Equities

ACRVAcrivon Therapeutics,   3.00   
0%
18.0%
MLYSMineralys Therapeutics,   1.56   
0%
9.0%
AVTEAerovate Therapeutics   1.19   
0%
7.0%
ANEBAnebulo Pharmaceuticals   0.77   
0%
4.0%
PHVSPharvaris   0.05   
1.0%
0%
ANTXAN2 Therapeutics   0.74   
4.0%
0%
CADLCandel Therapeutics   1.06   
6.0%
0%
MOLNMolecular Partners   1.87   
11.0%
0%
PMVPPmv Pharmaceuticals   2.56   
15.0%
0%
ADAGAdagene   2.86   
17.0%
0%
SCPHScpharmaceuticals   3.38   
20.0%
0%
KTTAPasithea Therapeutics   4.51   
27.0%
0%
PEPGPepGen   5.58   
34.0%
0%
DMACDiaMedica Therapeutics   7.31   
44.0%
0%
RZLTRezolute   8.11   
49.0%
0%
ACXPAcurx Pharmaceuticals   16.28   
100.0%
0%

Additional Tools for Monopar Stock Analysis

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.